Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Strike With Bortezomib in Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with multiple myeloma currently or previously enrolled on UARK 98-026 and currently event-free at the time of the evaluation.~* Performance status of 0-2 based of Southwest Oncology Group (SWOG) criteria~* Previously documented platelet count \> 75,000/ul within a 35 days prior to enrollment~* Previously documented peripheral absolute neutrophil count \>1,000/ul within 35 days prior to enrollment.~* Adequate renal function~* Signed informed consent~* Female subject is post-menopausal or willing to use acceptable birth control~* Male subjects agree to use acceptable method of contraceptive~Exclusion Criteria:~* Hypersensitivity to Bortezomib, boron, or mannitol~* Female subject is pregnant or breastfeeding~* Experienced myocardial infraction within 6 months prior to enrollment~* Received other investigational new drugs within 14 days before enrollment~* Received any anti-myeloma therapy within 14 days~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* Diagnosed or treated for another malignancy within 3 years of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib/Treatment Arm (Type: ACTIVE_COMPARATOR): Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
- Observation Arm (watchful waiting) (Type: NO_INTERVENTION): monitor myeloma parameters every 3-6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).